logo
Influenza rates are 'very high' in Indiana. How to protect yourself

Influenza rates are 'very high' in Indiana. How to protect yourself

Yahoo12-02-2025
Indiana is seeing "very high" rates of influenza activity in emergency rooms and primary care offices across the state, as national cases of influenza hit a 15-year high.
Influenza rates in Indiana jumped from high to very high Tuesday, according to Indiana Department of Health data. Indiana's influenza uptick is in line with activity in other states as flu season hits its seasonal peak, said state epidemiologist Eric Hawkins.At the same time, other respiratory viruses — like respiratory syncytial virus (RSV), the common cold and coronavirus —are also circulating.
Most pharmacies have at-home tests available to test for the flu and coronavirus. However, other respiratory illnesses, such as RSV, require testing at a primary or urgent care office.
But this week has been one of the highest influenza peaks since the coronavirus pandemic.
Elderly patients and infants are among the most vulnerable patients. Indiana has recorded 57 influenza-related deaths this season as of Tuesday, with people over the age of 65 accounting for 41 of the deaths.
No Indiana infants under the age of four have died from influenza this year, according to IDOH.
In the past week, 13% of children under four years old visiting the emergency room presented signs of influenza, based on state data collected from 119 hospital emergency rooms and 23 urgent care centers.
"Right now, the important thing is it's respiratory season, so we have lots of things circulating, and the reason we have this information out there is to make people aware that there are things that they can do to prevent illness and respiratory illnesses," Hawkins said.
Influenza or flu typically presents with a high fever (over 100 degrees) accompanied by a cold or sore throat. Influenza spreads through person-to-person interactions, usually when a sick person coughs, sneezes or talks.
Vaccines can prevent severe infections and medical complications from the flu, said Dr. John Christenson, associate medical director of pediatric infection prevention at Riley Hospital for Children.
It's not too late for patients to receive the flu vaccine from a pharmacy or primary care provider, Christenson said. The vaccine takes up to 10 days to take effect.
"We hope that [parents] consider that influenza is still here and get this flu vaccine, so they can protect their family," Christenson said. "The vaccine is not a perfect vaccine. We've known that for decades. It may not prevent infection, but one thing we are pretty certain of is that the vaccine prevents death and hospitalizations."
Those who are elderly, immunocompromised or under the age of four can develop severe complications with influenza. If parents notice children having difficulty breathing or not taking enough food or fluids, they should seek additional medical care, Christenson said.
Even those vaccinated can still catch influenza. People can protect themselves and others with the "three C's," Hawkins said: cleaning hands and surfaces regularly; covering one's mouth when coughing; and containing the virus by staying home if ill.
"It does fluctuate and go up and down, but the take home message here with influenza always around is, what are the things you could do to prevent illness? And I think that's one thing that we can help with," Hawkins said.
Flu season runs from October to May, with peaks varying year to year. Doctors expect flu activity to start to decrease in March.
Flu rates reached unusual lows in the 2020-21 winter season due to widespread masking. However, in the last three years, flu rates in the colder months have ticked back up.
More: Flu has officially hit a second high in the US: Know the symptoms
The flu and COVID-19 have several symptoms in common. Here's how to tell the difference between the two viruses:
Alysa Guffey covers business and development for IndyStar. Have a story or tip? Contact her at amguffey@gannett.com.
This article originally appeared on Indianapolis Star: Flu rates are 'very high' in Indiana. How to prevent catching irus
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Enanta Pharmaceuticals to Participate in the H.C. Wainwright
Enanta Pharmaceuticals to Participate in the H.C. Wainwright

Business Wire

time7 hours ago

  • Business Wire

Enanta Pharmaceuticals to Participate in the H.C. Wainwright

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. 'HCW@Home' series. A live webcast of the event will be accessible by visiting the 'Events and Presentations' section on the 'Investors' page of Enanta's website at or by registering here. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing Hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information.

Warning over serious virus affecting newborns after surge in cases
Warning over serious virus affecting newborns after surge in cases

Yahoo

time13 hours ago

  • Yahoo

Warning over serious virus affecting newborns after surge in cases

Britain should prepare for a surge in a potentially serious virus following a record number of cases in Australia, health experts have warned. NHS officials said the Australian winter is often a reliable indicator of how viruses will spread in the UK. Following a spike in respiratory syncytial virus (RSV) cases in Australia, officials have confirmed that cases have been steadily rising in England since the beginning of 2025. NHS England has encouraged pregnant women to receive the vaccine which guards against RSV in order to protect their newborn babies. The health service said the virus is a leading cause of death among babies and the primary cause of hospital admissions for children. READ MORE: Girl, four, dies after incident at water park READ MORE: Full list of air fryers recalled as households told 'stop using' Kate Brintworth, chief midwifery officer for NHS England, said: "While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." Expectant mothers can receive the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the vaccination and NHS England will begin inviting people to come forward in the coming weeks. RSV is a frequent cause of coughs and colds. However, certain individuals, including infants and adults over the age of 75, are at high risk of becoming seriously ill from the virus. In infants, RSV is a common cause of a chest infection known as bronchiolitis. Last week, data demonstrating the effectiveness of the vaccine was published by the UK Health Security Agency. The agency stated that the jab for expectant mothers can prevent 72% of hospital admissions for their babies. Furthermore, the vaccine is 82% effective at preventing hospital admissions for RSV among older adults, according to the UKHSA. For the latest news and breaking news visit Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you by signing up to our daily and breaking newsletter. Sign up to our breaking news newsletter here. Follow us on X @LivECHONews or on Bluesky @ - official Liverpool ECHO accounts - real news in real time. We're also on Facebook/theliverpoolecho - your must-see news, features, videos and pictures throughout the day from the Liverpool ECHO.

RSV Jab Shields Older Adults from Hospitalisation
RSV Jab Shields Older Adults from Hospitalisation

Medscape

timea day ago

  • Medscape

RSV Jab Shields Older Adults from Hospitalisation

The UK Health Security Agency (UKHSA) has reported that the respiratory syncytial virus (RSV) vaccine is around 82% effective in preventing hospitalisation among adults aged 75-79. The data come from a study run in partnership with Nottingham University Hospitals and other NHS trusts. UKHSA called the results 'strong protection'. The study used data from a hospital-based sentinel surveillance system covering 14 hospitals in England. It included adults admitted for acute respiratory infections between 1 October 2024 and 31 March 2025. Of 1006 adults hospitalised with acute respiratory infections (ARI), 173 (17.2%) had RSV infection. Vaccine Efficacy by Clinical Subgroup Data showed vaccine efficacy against hospitalisation of: 82.3% for any RSV-associated ARI 86.7% for severe cases needing oxygen supplementation 88.6% for lower respiratory tract infection, including pneumonia 77.4% for exacerbations of chronic lung disease 78.8% for exacerbations linked to chronic heart disease, lung disease, or frailty 72.8% for adults with immunosuppression Maternal RSV Vaccination Also Effective The UKHSA also reviewed data from the maternal RSV vaccination programme, introduced alongside the older adults programme in September 2024. A separate study, published in The Lancet Child & Adolescent Health , found the maternal RSV vaccine reduced infant hospitalisation risk by 72% when given more than 14 days before birth. Both programmes use Pfizer's bivalent pre-F vaccine, Abrysvo). The programme for older adults offers the vaccine to those turning 75, as well as a one-off catch-up campaign for all adults aged 75-79 years. The maternal programme offers the vaccine from 28 weeks of pregnancy. Uptake Rates Vary Across Groups By 30 June, uptake among eligible older adults had risen to 62.9%, up from 60.3% in March. Among 36,657 women who gave birth in March, 54.7% had received the RSV vaccine during pregnancy. Coverage in the maternal programme varied by ethnic group. Uptake Uptake ranged from 73.3% among women of Chinese ethnicity to 26.4% among Black and Black British Caribbean women. RSV Seasonality and Surveillance Findings RSV activity typically starts in October. Bronchiolitis, the main clinical presentation in infants, is primarily caused by risk of hospitalisation with RSV infection is highest among babies born in late summer or autumn. The UKHSA's first annual RSV report reviewed the 2024-2025 season. It found: RSV activity began around mid-October across all UK nations It peaked between 18 November and 8 December (weeks 47 to 49) It declined to baseline levels by late February (weeks 7-8 of 2025) Primary care surveillance included around 300 GP practices in England, which swab patients presenting with ARI. Peak RSV positivity was: 53.1% in children under 5 during week 46 (11-17 November) 18.5% in adults aged 75 and over during week 49 (2-8 December) Hospital emergency department data also showed that bronchiolitis in infants under 1 year peaked in late November. MHRA Warns of Guillain-Barré Syndrome Risk In July, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety alert on RSV vaccines. Clinicians are advised to monitor for symptoms of Guillain-Barré syndrome (GBS) following vaccination. GBS is an acute demyelinating disease affecting the peripheral nervous system. Early symptoms include tingling, numbness, or pins and needles in the feet and hands, followed by muscle weakness and difficulty moving joints. In some cases, it can progress to breathing difficulties, drooping facial muscles, problems with swallowing or speech, and double vision. Although rare, GBS can be fatal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store